Pall Corporation, a global leader in filtration, separation and purification, announced a strategic alliance with Applied Science, Inc. (“ASI”) where Pall will act as the exclusive North American distributor of the HemoFlow™ 400 Blood Donation Monitor and Mixer; adding to Pall’s industry-leading family of blood collection and filtration products. Blood centers will now have access to a fully integrated collection and filtration solution from Pall, including a complete data management software system that improves the efficiency and profitability of blood center operations.
“With ASI’s HemoFlow 400 as part of our offering, Pall is providing a single-source solution that optimizes collection yields, product quality and blood center revenue streams,” said Allan Ross, President, Pall Medical.
The fully automated HemoFlow 400 combines a proprietary mixing action with a collection tracking system to maximize the use of whole blood donations. To further enhance efficiency, ensure accuracy and protect blood units, the HemoFlow 400 both audibly and visually guides users through the donation process and displays flow rate, elapsed time, current and target volume, total weight collected, and any relevant messages in up to nine languages.
With its small design and light weight, the HemoFlow 400 is highly flexible; can be used for both mobile and fixed site donations and, with its off-the-floor mounting, requires no footprint in tight spaces. It is FDA 510k market cleared, CE-marked, and comes with a 3-year limited warranty.
Recognizing the value of the HemoFlow 400 in accelerating automation at their local sites, New York Blood Center (NYBC), Virginia Blood Services, and San Diego Blood Bank have become major customers of the system.
San Diego Blood Bank (SDBB) Collection Staff have used the HemoFlow Mixer/Monitor for three years, according to Bonnie Welch, Director of Collections at the SDBB. “Currently we are using them in 100% of our collection sites and our self contained bloodmobiles. Soon all of our room set-ups will also have them. Staff unanimously like the devices for their ease-of-use, self mixing of blood units, continuous information readouts, visual/audio warnings and alarms for slow flow, etc., which helps save donations. They are also versatile because of the mixer/monitor and scale only options. Staff and donors alike appreciate the freedom to interact during donation; that was not possible when manual mixing of blood units was required. Our goal is to give every donor a ‘delightful’ experience which is directly related to personal attention. With the HemoFlow Mixer/Monitor, we can do just that.”
The HemoFlow 400 perfectly complements Pall’s closed system collection and filtration sets by ensuring the consistency and accuracy of draw volume, and safeguarding the integrity of collections. This integrated offering for blood centers is an ideal solution for optimizing workflow and improving product yields, safety and availability.
In partnering with Pall for the distribution and integration of the HemoFlow 400 within its family of blood collection products, ASI is taking advantage of Pall’s major presence in the life sciences marketplace.
“Our strategic alliance with Pall leverages the credibility and distribution access that will assure customer satisfaction and deliver added-value to the blood banks that rely on Pall products to keep their operations running smoothly,” says Jonathan Morgan, ASI President & CEO.
Pall Medical is a key supplier to the blood banking industry. Pall’s blood collection, filtration and transfusion bag sets have become the industry standard, Pall’s complete product family encompasses each step in the collection, processing, freezing and transfusion process. For more information, log onto www.pall.com/medical.
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.
About Pall Corporation
Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The company’s engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 5